Circulating tumor cells, disease progression, and survival in metastatic breast cancer M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ... New England Journal of Medicine 351 (8), 781-791, 2004 | 5311 | 2004 |
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ... Journal of clinical oncology 23 (7), 1420-1430, 2005 | 1365 | 2005 |
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ... Clinical Cancer Research 12 (14), 4218-4224, 2006 | 1224 | 2006 |
Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ... Clinical Cancer Research 12 (21), 6403-6409, 2006 | 967 | 2006 |
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer SE Jones, J Erban, B Overmoyer, GT Budd, L Hutchins, E Lower, ... Journal of Clinical Oncology 23 (24), 5542-5551, 2005 | 684 | 2005 |
Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study S Seicean, A Seicean, JC Plana, GT Budd, TH Marwick Journal of the American College of Cardiology 60 (23), 2384-2390, 2012 | 372 | 2012 |
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR DG Hicks, SM Short, NL Prescott, SM Tarr, KA Coleman, BJ Yoder, ... The American journal of surgical pathology 30 (9), 1097-1104, 2006 | 334 | 2006 |
Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of … MJ Ellis, VJ Suman, J Hoog, R Goncalves, S Sanati, CJ Creighton, ... Journal of Clinical Oncology 35 (10), 1061, 2017 | 322 | 2017 |
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. CW Taylor, S Green, WS Dalton, S Martino, D Rector, JN Ingle, NJ Robert, ... Journal of Clinical Oncology 16 (3), 994-999, 1998 | 301 | 1998 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27—a randomized controlled phase III trial PE Goss, JN Ingle, KI Pritchard, MJ Ellis, GW Sledge, GT Budd, ... Journal of clinical oncology 31 (11), 1398, 2013 | 282 | 2013 |
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre … WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ... The lancet oncology 18 (8), 1089-1103, 2017 | 268 | 2017 |
NCCN guidelines insights: bone cancer, version 2.2017 JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ... Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 2017 | 267 | 2017 |
Estrogen receptor mutations in tamoxifen-resistant breast cancer PS Karnik, S Kulkarni, XP Liu, GT Budd, RM Bukowski Cancer research 54 (2), 349-353, 1994 | 256 | 1994 |
Novel prognostic immunohistochemical biomarker panel for estrogen receptor–positive breast cancer BZ Ring, RS Seitz, R Beck, WJ Shasteen, SM Tarr, MCU Cheang, ... Journal of clinical oncology 24 (19), 3039-3047, 2006 | 210 | 2006 |
Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure S Seicean, A Seicean, N Alan, JC Plana, GT Budd, TH Marwick Circulation: Heart Failure 6 (3), 420-426, 2013 | 209 | 2013 |
Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221) CB Ambrosone, GR Zirpoli, AD Hutson, WE McCann, SE McCann, ... Journal of Clinical Oncology 38 (8), 804, 2020 | 188 | 2020 |
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy Y Zhang, AM Sieuwerts, M McGreevy, G Casey, T Cufer, A Paradiso, ... Breast cancer research and treatment 116, 303-309, 2009 | 171 | 2009 |
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. RL Miller, RM Bukowski, GT Budd, J Purvis, JK Weick, K Shepard, ... Journal of Clinical Oncology 6 (5), 880-888, 1988 | 156 | 1988 |
Physical activity before, during, and after chemotherapy for high-risk breast cancer: relationships with survival RA Cannioto, A Hutson, S Dighe, W McCann, SE McCann, GR Zirpoli, ... JNCI: Journal of the National Cancer Institute 113 (1), 54-63, 2021 | 140 | 2021 |
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma RM Bukowski, W Sharfman, S Murthy, P Rayman, R Tubbs, J Alexander, ... Cancer research 51 (16), 4199-4205, 1991 | 136 | 1991 |